BWBenfang Wang

Benfang Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Benfang Wang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Dandan Lin

    MOH Key Lab of Thrombosis and Hemostasis, Collaborative Innovation Center of Hematology-Thrombosis and Hemostasis Group, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, China

    1 shared publication
  • Frank Luh

    Sino-American Cancer Foundation, Temple City, California

    1 shared publication
  • Jianjiang Yu

    Department of Clinical Laboratory, Jiangyin People's Hospital Affiliated to Nantong University, Jiangyin, China

    1 shared publication
  • Qi Zhang

    School of Medicine, Zhejiang University City College, Hangzhou, Zhejiang, China

    1 shared publication
  • Ting Wang

    Department of Chinese-Western Medicine Integrative Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China

    1 shared publication
  • Xiyong Liu

    Department of General Surgery and Laboratory of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, No. 1665 Kongjiang Road, Shanghai 200092, China; Institute of Biliary Tract Disease Research, Shanghai Jiao Tong University School of Medicine, No. 1665 Kongjiang Road, Shanghai 200092, China

    1 shared publication

Latest Publications

  • Open Access

    Kinesin family member 11 is a potential therapeutic target and is suppressed by microRNA‐30a in breast cancer

    by Benfang Wang, Jianjiang Yu, Zhenjiang Sun, Frank Luh, Dandan Lin, Ying Shen, Ting Wang, Qi Zhang, Xiyong Liu

    Kinesin family member 11 (KIF11) is a plus end‐directed kinesin indispensable for the formation of the bipolar spindle in metaphase, where it objects to the action of minus end‐directed molecular motors. Here, we hypothesize that KIF11 might be a therapeutic target of breast cancer and regulated by miR‐30a. Cell Counting Kit 8 assays were used to investigate cell proliferation. Invasion assays were used to survey the motility of cells. Kaplan‐Meier and Cox proportional analyses were employed for this outcome study. The prognostic significance and performance of KIF11 were validated on 17 worldwide independent microarray datasets and two The Cancer Genome Atlas‐Breast Invasive Carcinoma sets. microRNA was predicted targeting KIF11 through sequence alignment in microRNA.org and confirmed by coexpression analysis in human breast cancer samples. Dual‐luciferase reporter assays were employed to validate the interaction between miR‐30a and KIF11 further. Higher KIF11 mRNA levels and lower miR‐30a were significantly associated with poor survival of breast cancer patients. Inhibition of KIF11 by small‐hairpin RNA significantly reduced the proliferation and invasion capabilities of the breast cancer cells. Meanwhile, downregulation of KIF11 could enhance the cytotoxicity of adriamycin in breast cancer cell lines MCF‐7 and MDA‐MB‐231. A population study also validated that chemotherapy and radiotherapy significantly improved survival in early‐stage breast cancer patients with low KIF11 expression levels. Further bioinformatics analysis demonstrated that miR‐30a could interact with KIF11 and validated by dual‐luciferase reporter assays. Therefore, KIF11 is a potential therapeutic target of breast cancer. miR‐30a could specifically interact with KIF11 and suppress its expression in breast cancer.